 |
Dealmaker's News: May 2011
Sponsored by:
IBC: Biosimilars Asia
Grand Hyatt Shanghai, China | 23-26 May, 2011
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the only conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
- Discover latest legal challenges and patent expiries
- What you need to know about cost-effective clinical development
- Explore game-changing moves, the “unholy alliances”, partnerships and collaborations
- Equip yourself with the most recent global market outlook and pharmerging markets
- Thought-provoking discussions featuring innovators, generics, biosimilars and industry thought-leaders
- All you need to know about Biosimilarity, bioequivalence, substitutability, safety and patient acceptance concerns
- Exclusive Pre & Post conference biosimilar development workshops and strategy briefing you won’t want to miss out
- A must-attend for CSOs & Heads of R&D with well-researched topics
- Opportunity to network with industry peers
To register for a place at this event, please visit the event website.
 |
- Editor's corner
- In the news
- Partnering reports
- Forthcoming events
-
Scorecard update
|
Editor's corner
Hi,
After publishing our Companion Diagnostics Partnering Terms & Agreements report back in January and subsequently re-issuing this in April, this has now become our best-selling report of 2011. The report highlights the current relevance of the subject and companies' eagerness to learn more about the types of deals being negotiated in this area and under what terms these deals are being agreed upon.
Order now | more details | request sample pages
You may have seen our email message yesterday relating to Current Agreements - if you didn't, we have now made it possible to access the deals and alliances database for as little as 1 month! This is great news if you are perhaps a consultant working on a short-term project, or simply have a limited budget without the need for long-term access. Here are your options:
- 1 month (from $1,000)
- 3 month (from $2,000)
- 6 month (from $3,000)
- 12 month (from $5,000)
- 24 month (from $8,000)
Subscribe now | request your free trial | more details
If you have any questions about any of our products relating to either Current Partnering or Current Agreements, please contact me and I'll be happy to help you.
Thanks and best wishes,
Claire.
In the news
Top deal-related news from the last few days:
Full details can be seen at Current Agreements.
Follow our news pages online at Current Partnering
View the latest breaking deals at Current Agreements
Request your free two-day trial of Current Agreements
Current Partnering report titles
Personalized Medicine Partnering Terms & Agreements
Pharmacogenomics Partnering Terms & Agreements
Partnering & M&A Agreements in Pharma & Biotech Yearbook: 2010
Companion Diagnostics Partnering Terms & Agreements - 2nd edition
Biomarker Partnering Terms and Agreements - 2nd edition
Partnering Terms and Agreements in Diagnostics, 2nd edition
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
Distribution Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Practical Guide to Finding Partners in Pharma & Biotech, 4th edition
Forthcoming Events
Here are some of our suggested events taking you through 2011:
EuroMedTech
Euro-Biotech Forum
C21 BioVentures
BIO International Convention
Molecular Diagnostics for Cancer Drug Development
WORLDx Congress
BioPharm America
BIO-Europe
euroPLX 47
Scorecard update
Updated 10 May, 2011
Our Scorecard Index provides a simple overview of recent partnering and M&A activity - see it now - Scorecard Index.
In additon, we track the leading deals by value in the current year, plus a compendium of top deals by value since 2000 - view details at Scorecard.
Articles of the month
Alkermes buys up Elan Drug Delivery Technology Unit for $960m
10 May, 2011
Alkermes agreed to buy Elan drug Technologies, the drug delivery unit of Elan Corporation, in a deal valued at $960m. The deal will be funded by a $50 million cash payment... More
Teva outbids Valeant to acquire Cephalon
2 May, 2011
Cephalon has accepted a bid from Teva which values the company at $6.8 billion - some $1.1 billion more than the Valeant offer of several weeks ago. The accepted offer brings to an end what looked like... More
J&J nabs Synthes for $21.3 billion in biggest deal of the year to date
28 April, 2011
Johnson and Johnson have confirmed their acquisition of the Swiss medical company Synthes for $21.3 billion, following mounting speculation in recent weeks. More
Contact us!
Claire Nicholson, Editor
Web: http://www.CurrentPartnering.com
Mail: Wildwood Ventures Ltd., Eco Business Centre, Amy Johnson Way, Clifton Moor, York, YO30 4AG, United Kingdom
Tel: +44 1904 693200
Fax: +44 8703 305993
Email
Advertising and sponsorship
Current Partnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.
Or, contact us to discuss your requirements.
About Current Partnering
Current Partnering is an online provider of best practice, business information and intelligence for deal makers. We search out the latest information so you don’t have to and place it in one location, saving you precious time and resources.
|
 |
 |
 |
Current Partnering reports:
 |
Current Partnering is a leading publisher of partnering business intelligence
Here is what our clients say about our reports:
"The information you provide is excellent and we look forward to doing more business with you in the future."
..."You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date..."
|
|
 |